APA PsycNET Our Apologies! - The following features are not available with your current Browser configuration. - get an abstract for a record - mobile App popup - get an abstract for a record - get all abstracts for all records - page navigation - memorize search form information - display database popup information - adjust limits on search form
Skip Navigation

PsycNET®

Purchase Full Text
Add to Cart
$11.95
PsycARTICLES :
Citation and Abstract
The emperor's new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration.
Kirsch, Irving; Moore, Thomas J.; Scoboria, Alan; Nicholls, Sarah S.
Prevention & Treatment, Vol 5(1), Jul 2002, No Pagination Specified Article 23.
Posted July 15, 2002. This article reports an analysis of the efficacy data submitted to the U.S. Food and Drug Administration for approval of the 6 most widely prescribed antidepressants approved between 1987 and 1999. Approximately 80% of the response to medication was duplicated in placebo control groups, and the mean difference between drug and placebo was approximately 2 points on the 17-item (50-point) and 21-item (62-point) Hamilton Depression Scale. Improvement at the highest doses of medication was not different from improvement at the lowest doses. The proportion of the drug response duplicated by placebo was significantly greater with observed cases (OC) data than with last observation carried forward (LOCF) data. If drug and placebo effects are additive, the pharmacological effects of antidepressants are clinically negligible. If they are not additive, alternative experimental designs are needed for the evaluation of antidepressants. (PsycINFO Database Record (c) 2012 APA, all rights reserved)